DLX-105

• Description:

  DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research[1].

• UNSPSC:

  12352203

• Target:

  IFNAR; Interleukin Related; TNF Receptor

• Related Pathways:

  Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  [DLX-105]

• References & Citations:

  [1]Tsianakas A, et al. The single-chain anti-TNF-α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis. Exp Dermatol. 2016 Jun;25 (6) :428-33.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported